Cargando…
Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population?
Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the devel...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609986/ https://www.ncbi.nlm.nih.gov/pubmed/37895858 http://dx.doi.org/10.3390/ph16101387 |
_version_ | 1785128143988719616 |
---|---|
author | Tayal, Rohit Yasmin, Sabina Chauhan, Samrat Singh, Thakur Gurjeet Saini, Monika Shorog, Eman Althubyani, Maryam M. Alsaadi, Baiaan H. Aljohani, Fatimah Alenazi, Maram A. Abutaily, Sarah A. Ansari, Mohammad Yousuf |
author_facet | Tayal, Rohit Yasmin, Sabina Chauhan, Samrat Singh, Thakur Gurjeet Saini, Monika Shorog, Eman Althubyani, Maryam M. Alsaadi, Baiaan H. Aljohani, Fatimah Alenazi, Maram A. Abutaily, Sarah A. Ansari, Mohammad Yousuf |
author_sort | Tayal, Rohit |
collection | PubMed |
description | Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the development of other serious health problems, it can have detrimental consequences for patients. This article explores the correlation between persistent proton pump inhibitor (PPI) use and hypertension, a common cardiovascular ailment. While PPIs are beneficial in treating various gastrointestinal problems, their availability without a prescription has resulted in self-medication and long-term use without medical monitoring. Recent findings have revealed a link between long-term PPI usage and increased cardiovascular risks, particularly hypertension. This study investigates the intricate mechanisms underlying PPI’s effects, focusing on potential pathways contributing to hypertension, such as endothelial dysfunction, disruption of nitric oxide bioavailability, vitamin B deficiency, hypocalcemia, and hypomagnesemia. The discussion explains how long-term PPI use can disrupt normal endothelial function, vascular control, and mineral balance, eventually leading to hypertension. The article emphasizes the significance of using PPIs with caution and ongoing research to better understand the implications of these medications on cardiovascular health. |
format | Online Article Text |
id | pubmed-10609986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106099862023-10-28 Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? Tayal, Rohit Yasmin, Sabina Chauhan, Samrat Singh, Thakur Gurjeet Saini, Monika Shorog, Eman Althubyani, Maryam M. Alsaadi, Baiaan H. Aljohani, Fatimah Alenazi, Maram A. Abutaily, Sarah A. Ansari, Mohammad Yousuf Pharmaceuticals (Basel) Review Balancing the therapeutic advantages of a medicine with its possible risks and side effects is an important part of medical practice and drug regulation. When a drug is designed to treat a particular disease or medical condition ends up causing additional risks or side effects that lead to the development of other serious health problems, it can have detrimental consequences for patients. This article explores the correlation between persistent proton pump inhibitor (PPI) use and hypertension, a common cardiovascular ailment. While PPIs are beneficial in treating various gastrointestinal problems, their availability without a prescription has resulted in self-medication and long-term use without medical monitoring. Recent findings have revealed a link between long-term PPI usage and increased cardiovascular risks, particularly hypertension. This study investigates the intricate mechanisms underlying PPI’s effects, focusing on potential pathways contributing to hypertension, such as endothelial dysfunction, disruption of nitric oxide bioavailability, vitamin B deficiency, hypocalcemia, and hypomagnesemia. The discussion explains how long-term PPI use can disrupt normal endothelial function, vascular control, and mineral balance, eventually leading to hypertension. The article emphasizes the significance of using PPIs with caution and ongoing research to better understand the implications of these medications on cardiovascular health. MDPI 2023-09-30 /pmc/articles/PMC10609986/ /pubmed/37895858 http://dx.doi.org/10.3390/ph16101387 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tayal, Rohit Yasmin, Sabina Chauhan, Samrat Singh, Thakur Gurjeet Saini, Monika Shorog, Eman Althubyani, Maryam M. Alsaadi, Baiaan H. Aljohani, Fatimah Alenazi, Maram A. Abutaily, Sarah A. Ansari, Mohammad Yousuf Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title | Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title_full | Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title_fullStr | Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title_full_unstemmed | Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title_short | Are Proton Pump Inhibitors Contributing in Emerging New Hypertensive Population? |
title_sort | are proton pump inhibitors contributing in emerging new hypertensive population? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609986/ https://www.ncbi.nlm.nih.gov/pubmed/37895858 http://dx.doi.org/10.3390/ph16101387 |
work_keys_str_mv | AT tayalrohit areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT yasminsabina areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT chauhansamrat areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT singhthakurgurjeet areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT sainimonika areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT shorogeman areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT althubyanimaryamm areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT alsaadibaiaanh areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT aljohanifatimah areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT alenazimarama areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT abutailysaraha areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation AT ansarimohammadyousuf areprotonpumpinhibitorscontributinginemergingnewhypertensivepopulation |